NCT03374540 - Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients | Biotech Hunter

Enrollment

78,517

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions

Nonvalvular Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15/20 mg

DRUG

Vitamin K antagonist (VKA)

Individually adjusted dose

Trial Locations (1)

Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases, Multiple Locations